Cofoe Medical Technology Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Operating Revenue	3,526	3,252	2,842	2,706	2,869	2,129
Other Revenue	135.86	135.86	141.38	148.02	108.05	146.74
Revenue	3,662	3,387	2,983	2,854	2,977	2,276
Revenue Growth (YoY)	25.69%	13.56%	4.53%	-4.14%	30.82%	-4.19%
Cost of Revenue	1,720	1,619	1,468	1,670	1,839	1,296
Gross Profit	1,942	1,768	1,515	1,184	1,137	979.57
Selling, General & Admin	1,459	1,331	1,095	851.63	740.79	471.08
Research & Development	90.54	87.28	96.41	114.33	118.42	70.59
Other Operating Expenses	31.03	15.6	9.25	8.18	12.65	6.24
Operating Expenses	1,580	1,434	1,206	973.55	886.23	558.69
Operating Income	361.42	334.51	309.35	210.31	251.23	420.89
Interest Expense	-16.07	-16.07	-17.91	-13.5	-10.85	-6.81
Interest & Investment Income	31.95	42.27	54.71	82.02	102.64	14.41
Currency Exchange Gain (Loss)	-4.14	-4.14	0.52	0.16	0.36	-0.19
Other Non Operating Income (Expenses)	-4.94	-4.67	-1.9	-3.27	-2.49	-0.44
EBT Excluding Unusual Items	368.21	351.91	344.78	275.71	340.89	427.86
Impairment of Goodwill	-	-	-	-	-0.15	-
Gain (Loss) on Sale of Investments	44.95	49.84	9.4	-1.56	4.4	6.02
Gain (Loss) on Sale of Assets	-1.38	-1.37	5.88	4.59	6.47	0.14
Asset Writedown	8.39	0.18	-2.32	-2.24	-35.14	-0.05
Legal Settlements	1.45	1.45	2.19	-2.41	-	-0.16
Other Unusual Items	23.83	23.83	12.07	11.61	17.91	74.51
Pretax Income	445.45	425.84	372	285.71	334.39	508.33
Income Tax Expense	59.29	55.53	59.66	32.84	32.37	78.74
Earnings From Continuing Operations	386.16	370.32	312.34	252.87	302.02	429.59
Minority Interest in Earnings	1.07	1.29	-0.59	1.41	-0.34	-0.73
Net Income	387.23	371.61	311.75	254.28	301.68	428.86
Net Income to Common	387.23	371.61	311.75	254.28	301.68	428.86
Net Income Growth	28.24%	19.20%	22.60%	-15.71%	-29.65%	1.16%
Shares Outstanding (Basic)	204	204	204	205	208	165
Shares Outstanding (Diluted)	206	205	206	205	208	165
Shares Change (YoY)	-0.09%	-0.20%	0.46%	-1.70%	26.56%	5.47%
EPS (Basic)	1.90	1.83	1.53	1.24	1.45	2.60
EPS (Diluted)	1.88	1.81	1.51	1.24	1.45	2.60
EPS Growth	28.83%	19.87%	21.77%	-14.48%	-44.23%	-4.25%
Free Cash Flow	545.51	517.63	542.9	20.6	-540.87	-273.25
Free Cash Flow Per Share	2.65	2.52	2.64	0.10	-2.60	-1.66
Dividend Per Share	1.800	1.800	1.800	1.200	1.200	1.231
Dividend Growth	-	-	50.00%	-	-2.50%	-
Gross Margin	53.03%	52.20%	50.79%	41.48%	38.21%	43.05%
Operating Margin	9.87%	9.88%	10.37%	7.37%	8.44%	18.50%
Profit Margin	10.57%	10.97%	10.45%	8.91%	10.13%	18.85%
Free Cash Flow Margin	14.90%	15.28%	18.20%	0.72%	-18.17%	-12.01%
EBITDA	478.71	448.85	411.86	293.98	292.34	449.78
EBITDA Margin	13.07%	13.25%	13.81%	10.30%	9.82%	19.77%
D&A For EBITDA	117.29	114.33	102.51	83.67	41.11	28.89
EBIT	361.42	334.51	309.35	210.31	251.23	420.89
EBIT Margin	9.87%	9.88%	10.37%	7.37%	8.44%	18.50%
Effective Tax Rate	13.31%	13.04%	16.04%	11.49%	9.68%	15.49%
Revenue as Reported	3,387	3,387	2,983	2,854	2,977	2,276
Advertising Expenses	-	328.12	225.57	206.59	151.96	86.71

Source: S&P Global Market Intelligence. Standard template. Financial Sources.